Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Jul 15, 2023; 15(7): 1262-1270
Published online Jul 15, 2023. doi: 10.4251/wjgo.v15.i7.1262
Published online Jul 15, 2023. doi: 10.4251/wjgo.v15.i7.1262
Table 3 Incidence of drug toxicities in two groups of esophageal carcinoma patients, n (%)
| Indicators | Control group (n = 30) | Research group (n = 32) | χ2 | P value |
| Myelosuppression | ||||
| I-II | 13 (43.33) | 6 (18.75) | 4.403 | 0.036 |
| III-IV | 6 (20.00) | 2 (6.25) | 2.605 | 0.107 |
| Gastrointestinal reactions | ||||
| I-II | 15 (50.00) | 8 (25.00) | 4.147 | 0.042 |
| III-IV | 7 (23.33) | 3 (9.38) | 2.230 | 0.135 |
| Radiation esophagitis | ||||
| I-II | 14 (46.67) | 13 (40.63) | 0.230 | 0.632 |
| III-IV | 7 (23.33) | 6 (18.75) | 0.196 | 0.658 |
- Citation: Zhang TW, Zhang P, Nie D, Che XY, Fu TT, Zhang Y. Efficacy of concurrent chemoradiotherapy with thalidomide and S-1 for esophageal carcinoma and its influence on serum tumor markers. World J Gastrointest Oncol 2023; 15(7): 1262-1270
- URL: https://www.wjgnet.com/1948-5204/full/v15/i7/1262.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i7.1262